TRX319

Phase 2Biologic

TTr1X, Inc.

TRX319 is one of 18 biologic programs targeting Secondary Progressive Multiple Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Secondary Progressive Multiple SclerosisRecruiting

Secondary Progressive Multiple SclerosisPhase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Secondary Progressive Multiple Sclerosis

#DrugCompanyPhaseTrials

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Midamor

Novantrone

Glucophage

Rilutek

AAzurity Pharmaceuticals

Rituxan

3 7

Rhapsido

Novartis

Phase 3

1 8

Frexalimab

Sanofi

Phase 3

1 9

Treanda

AAzurity Pharmaceuticals

Phase 2

1 10

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1/2Recruiting

Secondary Progressive Multiple Sclerosis

NCT07477639

Clinical

Trials by Indication[1]

Secondary Progressive Multiple Sclerosis1 trial

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Recruiting·TTr1X, Inc.·Phase 1/2·NCT07477639·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TRX319. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRX319 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRX319. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tr1X, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: TTr1X, Inc.

TRX319

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Secondary Progressive Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News